The FDA revoked the emergency use authorization for the treatment of COVID-19 with chloroquine and hydroxychloroquine

, the U.S. Food and Drug Administration (FDA) issued a statement revoking the Emergency Use Authorization (EUA) for the treatment of COVID-19 hospitalized patients. On March 28, the FDA issued the emergency authorization.In its latest statement, the FDA said it determined that chloroquine and hydroxychloroquine may not be effective in treating COVID-19.This is based on the latest results from a large randomized clinical trial of hospitalized patients (similar to those authorized to use chloroquine and hydroxychloroquine). The results showed that hydroxychloroquine had no benefit in mortality or accelerated recovery. The results are consistent with other new data: chloroquine and hydroxychloroquine dosing programmes are unlikely to kill or suppress the viruses that cause COVID-19. All the scientific evidence available today suggests a lack of benefits.In addition, given persistent severe heart events and other potentially serious side effects, the potential benefits of chloroquine and hydroxychloroquine do not exceed the known and potential risks of authorized use."While other clinical trials continue to evaluate the potential benefits of these drugs in treating or preventing COVID-19, we determine that emergency use authorization is no longer appropriate," said Dr. Patrizia Cavazzoni, acting director of the FDA's Center for Drug Evaluation. We took this action after a rigorous assessment by scientists at our drug evaluation and research center. " (Biological exploration)